Placental Transfer of Propofol and Its Plasma Concentration in Cesarean Section

ZHAO Yi,ZHU Chun-xian,YU He-yong

2006-01-01

Abstract:To establish an HPLC method for the determination propofol in maternal vein plasma,umbili- cal vein plasma and umbilical artery plasma.To assess transplacental passage of propofol by measuring the levels in maternal and umbilical plasma at the time of delivery when propofol is used as an induction agent in obstetric anes- thesia for performing an elective cesarean section.Methods:Zorbax extend C_(18) column (5μm,4.6 mm×250 mm) was used;The mobile phase consisted of acetonitrile-water (4:1,adjusted pH to 4.0 with phosphoric acid),the flow rate was 1.0 mL·min~(-1),column temperature was 25℃,and the detection was set at 220 nm.The samples were deposited with ammonium sulfate.Intravenous and arterial propofol was administered as an anesthesia inducting agent at a bolus dose of 1.5 mg·kg~(-1) in 20 healthy women (ASA Ⅰ-Ⅱ).The propofol concentrations were measured by HPLC.Results:The linear range was 0.125-5μg·mL~(-1),r=0.9999 and the limit of detection was 0.05 μg·mL~(-1);The method recovery was 99.5%-104.2% (n=5).Within-day precision (RSD) was 1.4%- 3.3% (n=5),between-day precision (RSD) was 5.3%-7.6% (n=5).In all patients it took 6-12 min to de- liver the fetus.Apgar test scores were high in the 20 neonates.The mean value in maternal venous blood (MV) was (0.71±0.32)μg·mL~(-1)at the time of delivery.Propofol crossed the placental barrier with level in the umbilical vein blood(UV) of (0.35±0.21 ) μg·mL~(-1)and in the umbilical artery blood of (0.28±0.14)μg·mL~(-1).The C_(UV)/C_(MV) was 0.53±0.19 and C_(UA)/C_(UV) was 0.97±0.36.Maternal concentrations were always greater than umbili- cal venous concentrations at delivery(t=3.843,P0.01).A moderate linear correlation was found between C_(MV) and C_(UV)(r=0.451).Conclusions:The method is convenient and accurate,so it is suitable for the determination of propofol in human plasma.Propofol crossed the placental barrier quickly,but 1.5 mg·kg~(-1) dose have no apparent major adverse effects on the neonatal outcome.